Virat Kohli and Rohit Sharma are among just the four players who have featured in all 18 season of the Indian Premier League since its inception in 2008. Will the Mumbai Indians win against the in ...

Rohit Sharma surpassed Shikhar Dhawan to become the second-leading run-scorer in IPL history. Virat Kohli with 8326 runs to his name, remains on the top of the list. Meanwhile, courtesy of Rohit's ...

Virat Kohli and Rohit Sharma announced their retirements from T20Is following India's seven-run victory against South Africa in the final of the 2024 Men's T20 World Cup. Kohli announced it after ...

Gill believes Rohit isn't thinking about retiring after ... For instance, he reminded one, of Virat Kohli. "We saw Virat in the last match," he said. "Because he has played so many important ...

Apart from Rohit, Virat Kohli will be the other key batter in the Indian side against the arch-rivals on Sunday morning. In five games, Kohli has scored 308 runs, having been dismissed by Pakistan ...

"I want to clarify that I am not going anywhere, I am not retiring from this format," Rohit said in the press ... There has been speculation about Virat Kohli taking that step as well but the ...

Rohit, who was involved in Virat Kohli's run-out for a duck this afternoon, compensated for the error, by slamming 209 off 158 balls, studding it with 14 fours and 16 sixes. Backed up by half ...

MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial.

The Indian team had a thorough net session on Wednesday night, marked by visible inactivity of captain Rohit Sharma and vice-captain Shubman Gill. During the three-hour practice under the lights ...

That was Rohit Sharma after India's Champions Trophy triumph in Dubai on Sunday night. Hours later, he elaborated on the subject emphasising that he doesn't like thinking too far into the future.

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage non ...

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.